Natalizumab reduces MS relapses and disability--Cochrane review | TheMedGuru

themedguru.com — Dr Doug Brown, Head of Biomedical Research at theMS Society, said, "Natalizumab is a licensed treatment for MS in the UK and we have known for some time that it reduces relapse rates and progression of disability in people with relapsing remitting MS; it’s nice to see these findings confirmed in this review.” Oct 8, 2011 View in Crawl 4

Natalizumab reduces MS relapses and disability--Cochrane review  | TheMedGuru